Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
December 10, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7) AB-729 remains generally safe...
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 05, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the...
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
September 15, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:...
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
August 27, 2020 08:00 ET
|
Arbutus Biopharma Corporation; Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that...
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 07, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid...
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
May 18, 2020 16:05 ET
|
Arbutus Biopharma Corporation
Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected...
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
May 11, 2020 06:00 ET
|
Arbutus Biopharma Corporation
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11, 2020 (GLOBE NEWSWIRE) --...
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
March 26, 2020 16:05 ET
|
Arbutus Biopharma Corporation
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional...
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
March 05, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic...
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
February 10, 2020 08:00 ET
|
Arbutus Biopharma Corporation
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its...